Aims To evaluate the clinical and cost-effectiveness of left ventricular (LV) assist devices (LVADs) as a bridge to transplant (BTT) for people with end-stage heart failure (ESHF) through a systematic review and economic evaluation. Methods and results The systematic review and economic evaluation was conducted according to internationally recognized methods. The search strategy identified systematic reviews, randomized controlled trials, quasi-experimental studies, and observational studies evaluating the effects of LVADs on survival, functional capacity, and quality of life. Cost-effectiveness was assessed through a 5-year decision analytic model to estimate the incremental cost-effectiveness ratio of LVADs compared with usual care. Despite the poor methodological quality of the 18 studies included, LVADs appear beneficial improving survival, functional status, and quality of life. Adverse events are a serious concern. The economic evaluation showed that LVADs had a cost per quality adjusted life year of £65 242 (95% confidence interval £34 194-364 564). Sensitivity analysis showed that post-heart transplant survival gains, pre-heart transplant patient utility, and one-off costs associated with implantation determine cost-effectiveness. Conclusion Although LVADs appear clinically effective as a BTT for people with ESHF, it is unlikely that they will be cost-effective unless costs decrease or the benefits of their use increase.
Introduction
Heart transplantation is the accepted form of treatment for people with end-stage heart failure (ESHF), increasing the length and quality of life. 1, 2 Recent decreases in organ donation have restricted the availability of this treatment option to a few. [3] [4] [5] As a consequence, attention has focused on mechanical circulatory support as an alternative. Left ventricular (LV) assist devices (LVADs), which assist the function of the damaged left ventricle and help to restore normal haemodynamics and end organ flow, have been developed to provide support for patients as either a bridge to heart transplantation (BTT), a bridge to myocardial recovery, or as destination therapy. The continued development of LVADs during the last 10 years (miniaturization, low power use, and ease of implantation), declining costs, and improvements in associated care have made their wider use a reality. 6 Prior to the adoption of such new technologies, it is essential to evaluate the evidence of their associated benefits, risks, and costs. 7 This paper summarizes the results of a systematic review and economic evaluation commissioned by the Department of Health's Health Technology Assessment Programme in England and Wales to examine the clinical and cost-effectiveness of LVADs as a BTT for people with ESHF. 8 
Methods
We searched 18 electronic databases, including Medline, Cochrane, and Embase, from their inception to December 2004 for published and unpublished studies irrespective of language. 8 Additional references were identified through searching bibliographies of related publications and through contact with experts and manufacturers of devices.
We assessed systematic reviews, randomized controlled trials (RCTs), controlled clinical trials, cohort studies, case series, and & The European Society of Cardiology 2006. All rights reserved. For Permissions, please e-mail: journals.permissions@oxfordjournals.org case studies that evaluated currently available LVADs used as a BTT for people aged 16 years and over with ESHF for inclusion. We placed an emphasis on including studies that used the most rigorous study designs and that included an appropriate comparator, whether another LVAD, heart transplantation, or usual care while on the heart transplant waiting list. We excluded studies if they used LVADs as an emergency rescue strategy during surgery or during the peri-operative period only. Included studies had to assess survival, functional capacity, or quality of life as primary outcome measures. We included studies reported as abstracts or conference presentations if sufficient information was presented on their methodology and results. We assessed the quality of studies that met the stated inclusion criteria using standard criteria. 9, 10 Two reviewers independently applied the inclusion criteria, extracted data, and assessed methodological quality. A third reviewer independently resolved any differences. Standard information was extracted wherever possible. We assessed clinical effectiveness through a narrative comparison of different outcomes. Differences in, or insufficient details on, study designs, outcomes used, patient characteristics, or intervention used precluded meta-analysis.
Our economic evaluation was a cost-utility analysis based on a 5-year decision analytic model examining the benefits and costs of the use of LVADs as a BTT compared with usual medical care on the transplant waiting list. The evaluation focused on devices that were thought to be clinically effective in the systematic review. We adopted the perspective of the UK National Health Service for costs and benefits for 2003 (UK prices). Efficacy was analysed in terms of a change in patient survival, derived from the systematic review of clinical effectiveness. Survival data with an indication of time to an event (e.g. transplant) was limited, with only two studies presenting Kaplan-Meier survival curves for the 'bridged' period. 11, 12 The base case analysis used the study by Aaronson et al. 12 as it assessed survival to transplant, post-transplant, and overall survival and included a larger sample. Utility values originated from a study assessing patient utilities before and after LVAD implantation and post-heart transplantation using the standard gamble technique. 13 Costs originate from published sources, [14] [15] [16] [17] [18] [19] UK hospitals, and from device manufacturers, with resource-use scenarios developed from the systematic review of clinical effectiveness and expert advice specific to the UK setting ( Table 1) . We discounted costs at 6% and benefits at 1.5%. The 5-year time horizon adopted following LVAD implantation reflects the duration of the survival curve analysis. 12 We carried out a full range of one-way sensitivity analyses and threshold analysis on the LVAD-related costs to yield a cost per quality-adjusted life year (QALY) of £30 000 (the generally accepted cost-effectiveness threshold for the UK). 20 We generated confidence intervals around the mean using probabilistic sensitivity analysis (PSA), which randomly samples values from distributions imposed upon model parameters (costs, survival, and utilities) from published data. The confidence intervals represent the influence of parameter uncertainty upon the final cost-effectiveness outcome. These data are used to generate the cost-effectiveness acceptability curve (CEAC), which demonstrates the likelihood that the intervention is cost-effective across a range of thresholds. 21, 22 
Results

Systematic review of clinical effectiveness
Quantity and quality of evidence Eighteen studies assessing the clinical effectiveness of LVADs as a BTT met the inclusion criteria ( Figure 1) , with studies of the HeartMate implanted pneumatic and/or vented electric devices, 11, 12, [23] [24] [25] [26] [27] [28] Novacor N100, 29 Toyobo, 30 Thoratec, 31 Jarvik 2000, [32] [33] [34] [35] [36] [37] [38] and Micromed DeBakey. [39] [40] [41] [42] Only seven studies, all of them HeartMate, included a comparator, namely the Novacor, 24 inotropic agents, 12, 25, 28 or undefined medical care. 11, 26, 27 The methodological quality and the quality of reporting of studies, assessed using available reports, were judged to be weak providing the opportunity for bias ( Table 2 ). The generalizability of the studies was assessed through a comparison of key study characteristics, although limited information was provided (see Supplementary material online, Tables S1-S3). Studies tend to focus on male patients aged between 40 and 60 years who suffered from either dilated or ischaemic cardiomyopathy and were in New York Heart Association (NYHA) class IV.
Survival
Studies showed a survival benefit for people supported by an LVAD compared with usual medical care or the natural history of ESHF ( Table 3) . Comparison of the HeartMate LVAD with inotropic agents in three cohort analytic studies showed benefit for patients receiving the LVAD in survival and actuarial survival to transplantation and posttransplantation, although the difference in survival varied between the studies and the period of support and follow-up (range: 0-33%). 12, 25, 28 When comparing patients who had received the HeartMate LVAD with those on usual care, differences were more equivocal. Although a retrospective cohort analytic study found no difference in survival to transplant and following transplantation, 27 two retrospective cohort studies with historic controls found a benefit for patients who received an LVAD in survival to transplant (survival difference: 14 26 and 59%, 11 respectively) and survival post-transplantation (survival difference .60 days: 35%; 26 difference actuarial survival 1 and 2 years: 100% 11 ). Studies of other devices did not include a comparator and as a consequence only provide an indication of the additional survival gained from the LVAD compared with the poor prognosis evident from the natural history of the condition. The retrospective cohort analytic study of the Novacor LVAD compared post-transplantation survival of patients supported for ,30 days with those supported for 30 days, with no difference at 3 years. 29 A case series study of three patients with the Toyobo device showed a patient surviving to 64 days before dying, another patient surviving 119 days to transplantation, and a third still alive on the transplant waiting list at 390 days. 30 Two case reports of the Thoratec LVAD showed two patients surviving 21 and 60 days before transplantation. 31, 43 Four cohort studies of the MicroMed Debakey LVAD showed that 80% of patients survived at least 30 days post-implantation, with between 34 and 40% undergoing heart transplantation and 10-31% dying while on LVAD support. [39] [40] [41] [42] In two case series of the Jarvik 2000 LVAD, 70% were bridged to transplant with 30% having died while on LVAD support. 32, 44 Direct comparisons of the benefits of the different devices were limited. A controlled clinical trial compared the HeartMate LVAD with the Novacor LVAD showing limited difference in survival. 24 
Functional status
Two cohort studies of the HeartMate LVAD compared with historical controls showed that patients receiving an LVAD improved their functional status on the NYHA functional classification compared with those on usual care (LVAD: baseline 100% NYHA IV, 60 days post-transplant 94% NYHA I; usual medical care: baseline 83% NYHA IV, 60 days post-transplant 100% NYHA IV) or that expected given the natural history of the condition (LVAD: baseline 100% NYHA IV, 60 days post-transplant 94% NYHA I) (see Supplementary material online, Tables S1-S3). 11, 26 Similar improvements in functional status were experienced by patients receiving a Jarvik 2000 LVAD (LVAD: baseline 100% NYHA IV, post-implantation 70% NYHA I). 33 
Quality of life
A cohort study of the HeartMate LVAD 23 and a case series of the Jarvik 2000 45 provided the only evidence on changes in quality of life following device implantation (see Supplementary material online, Tables S1-S3). Although patients with the HeartMate LVAD reported statistically significant improvements on the Heart Failure Symptom Checklist (change in total score from baseline 20.07, P ¼ 0.002), changes on the Quality of Life Index (change in total score from baseline þ0.07, P ¼ not significant), Rating Question Form (change in total score from baseline 0, P ¼ not significant), and functional disability from the Sickness Impact Profile (change in total score from baseline þ0.02, P ¼ not significant) were equivocal. 23 Implantation of the Jarvik 2000 LVAD significantly improved quality of life for patients on all scales of the Minnesota Living with Heart Failure Questionnaire (changes from baseline to 1-month post-implantation: quality of life 223.7; physical subscale 215; emotional subscale 26.5). Improvements continued up to heart transplantation, with a slight worsening subsequently (changes from baseline to 1-month post-heart transplantation: quality of life þ12; physical subscale þ10; emotional subscale 21.5). 45 
Adverse events
Comparison of the HeartMate and Novacor LVADs showed similar rates of mortality from adverse events. 24 The HeartMate LVAD appeared to have a higher rate of device-related complications than the Novacor LVAD, including technical problems with controllers (70 vs. 10%, P , 0.001), device-related infections (55 vs. 20%, P ¼ 0.02), and driveline infections (45 vs. 20%, P ¼ 0.09). Other studies of the HeartMate device showed 20% of patients having mechanical device failures. 23, 25 Patients with the Novacor LVAD suffered slightly higher rates of bleeding (40 vs. 35%, P ¼ 0.7), re-operation (30 vs. 20%, P ¼ 0.5) and thromboembolic events (20 vs. 0%, P ¼ 0.1) than those with a HeartMate LVAD. 24 Other studies showed similar rates of thromboembolic events (0 26 and 5% 11 ) and rates of bleeding (39% 26 ) for the HeartMate device. Several studies showed that implantation of the HeartMate device resulted in right heart failure among 20% of patients 24, 26 and a study found that 40% of patients suffered psychiatric complications. 23 Studies of the HeartMate LVAD showed lower rates of adverse events following heart transplantation than for those receiving usual care, with fewer 11, 25, 27 Although the adverse events experienced by recipients of other LVADs were less clearly reported, it was evident that patients of the Novacor and Thoratec devices suffered from infection, thromboembolism, and required re-operations as a consequence. 29, 31, 43 Studies of the Jarvik 2000 LVAD reported technical problems with power cable connections breaking and incurring infections, but thromboembolic events, serious device infections, or haemolysis were not significant problems. 32, 33 Two cohort studies of the Micromed DeBakey LVAD reported a death, one from device-related sepsis 41 and another from unspecified adverse events. 39 
Cost-effectiveness of LVADs as a BTT for ESHF
With no relevant cost-effectiveness studies available, 8 an economic evaluation was produced to consider costeffectiveness in the UK. Comparison of the use of the Heart-Mate LVAD with usual medical care (base case) showed that the LVAD offered an additional 18.3 (discounted) months of survival per patient over the 5-year duration of the model at an additional cost of £99 475 (discounted), producing a base case cost per QALY of £65 242 ( Table 4) .
A range of one-way sensitivity analyses showed that the model is sensitive to survival gains, utility benefit in the pre-transplant period, and to the one-off costs associated with the LVAD (assessment, operation, and device costs) ( Table 5 ). Threshold analysis showed that LVADs only became cost-effective (assumed to be £30 000/QALY) when total LVAD costs were around £37 500 per patient compared with a base case cost £87 877. PSA using stochastic simulation was undertaken over 1000 iterations to produce 95% confidence limits of £34 194-364 564 per QALY. Cost and effectiveness pairs from the PSA were used to generate the CEAC (Figure 2) . The probability that the intervention is cost-effective at a cost/QALY of £30 000 is negligible.
Discussion
Our systematic review and economic evaluation have identified four important findings. First, LVADs appear beneficial as a BTT for patients with ESHF. They seem to benefit patients through improved survival, functional status, and quality of life when compared with inotropic agents, optimum care, or no care. However, their use is associated with serious adverse events, showing the need for improvements in patient care and design of devices. Second, there is insufficient evidence to discriminate between the different LVADs. The more established devices, such as the HeartMate, have a greater evidence base, but there are theoretical benefits to the newer non-pulsatile devices, such as the Jarvik 2000 and MicroMed Debakey. The benefits, including miniaturization, low power use, and ease of implantation, are beginning to be shown in practice. However, further investigations are needed to assess their long-term effectiveness, any adverse effects of non-pulsatility, and to take account of the continual developments in the devices, implantation techniques, and patient care that tend to occur with increased use. 6, 46 Third, that LVADs are not costeffective with a cost per QALY of £65 242, which is outside the assumed threshold for acceptability within the UK of £30 000 per QALY. Sensitivity analysis has shown that substantial reductions in the cost of the devices and/or operation or improvements in the length and quality of life after heart transplantation would be required before LVADs would be cost-effective. Finally, a scarcity of evidence and several methodological shortcomings in the available studies limit the findings. LVADs are a relatively new and fast changing technology with limited diffusion. As a consequence, the studies of efficacy are often observational, retrospective, and non-comparative and data for populating economic evaluations are imperfect. With the pace of development likely to continue, considerable efforts will be needed to ensure appropriate assessment of the technology. Initiatives are underway to improve the availability of comparative data but further trials are needed. 47 Although additional research may help to clarify the clinical and cost-effectiveness of these devices, it is clear that the lack of donor organs severely limits the opportunity for people to benefit from LVADs as a BTT. [3] [4] [5] 8 Heart donation has decreased by 14% in the USA 48 and 63% in the UK 8 between 1993 and 2003. Without an adequate provision of donor organs to meet the need and demand for heart transplantations, 49 it is likely that the future of LVADs lies in their use as long-term chronic support (destination therapy) for people with ESHF. 8 We applied consistent methods for undertaking systematic reviews and economic evaluations, with support throughout the process from an expert advisory group of clinicians, academics, and health professionals from the US and UK. We contacted manufacturers, the major specialist centres implanting LVADs in the UK, and authors of studies to try and obtain additional information, with varying success. Although the economic evaluation used the most up-to-date information available, it suffered from certain inadequacies including poor-quality evidence of clinical effectiveness, limited patient utility data, and cost data. It is likely that the poor evidence base reflects the fact that LVADs are a relatively new and fast changing technology, with limited diffusion. The pace of development is set to persist through the emergence of new devices and guidance for their use and management. It will be important to ensure that further primary research is appropriately conducted to high methodological standards and that this systematic review and economic evaluation is regularly updated.
Several areas for research have emerged, including the epidemiology of ESHF to assess incidence, prevalence, and characteristics of people; long-term (at least 2 years follow-up) RCTs focusing on head-to-head comparisons of different devices encompassing a broad range of patient groups and assessing patient survival, functional ability, quality of life, and adverse events; economic evaluations as part of clinical trials with prospective collection of data on quality of life, utilities, resources, and costs. Studies should assess the use of LVADs among different subgroups of people with ESHF, where clinical and cost-effectiveness may vary. In addition, given the declining availability of donor organs for heart transplantation and the potential for using LVADs as destination therapy for people with ESHF, it will be important to produce a systematic review of clinical and cost-effectiveness to assess the evidence base.
Conclusions
Although LVADs appear to be a clinically effective treatment as a BTT for people with ESHF, it is unlikely that they will be a cost-effective option unless the costs of the devices and their implantation are reduced substantially and/or the length and quality of life resulting from implantation are improved. With the limited and declining donation of hearts for transplantation, it appears that the future of the technology is in its use as destination therapy.
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